BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29305142)

  • 1. Oral bioavailability enhancement of β-lapachone, a poorly soluble fast crystallizer, by cocrystal, amorphous solid dispersion, and crystalline solid dispersion.
    Liu C; Liu Z; Chen Y; Chen Z; Chen H; Pui Y; Qian F
    Eur J Pharm Biopharm; 2018 Mar; 124():73-81. PubMed ID: 29305142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications.
    Qian F; Wang J; Hartley R; Tao J; Haddadin R; Mathias N; Hussain M
    Pharm Res; 2012 Oct; 29(10):2765-76. PubMed ID: 22315020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.
    Yan YD; Sung JH; Kim KK; Kim DW; Kim JO; Lee BJ; Yong CS; Choi HG
    Int J Pharm; 2012 Jan; 422(1-2):202-10. PubMed ID: 22085435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System.
    Baghel S; Cathcart H; O'Reilly NJ
    Mol Pharm; 2018 Sep; 15(9):3796-3812. PubMed ID: 30020788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing and Exploring the Differences in Dissolution and Stability Between Crystalline Solid Dispersion and Amorphous Solid Dispersion.
    Wang X; Zhang L; Ma D; Tang X; Zhang Y; Yin T; Gou J; Wang Y; He H
    AAPS PharmSciTech; 2020 Sep; 21(7):262. PubMed ID: 32975680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus.
    Joe JH; Lee WM; Park YJ; Joe KH; Oh DH; Seo YG; Woo JS; Yong CS; Choi HG
    Int J Pharm; 2010 Aug; 395(1-2):161-6. PubMed ID: 20580799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study.
    Chavan RB; Lodagekar A; Yadav B; Shastri NR
    Drug Deliv Transl Res; 2020 Aug; 10(4):903-918. PubMed ID: 32378174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of novel ibuprofen-loaded solid dispersion with improved bioavailability using aqueous solution.
    Park YJ; Kwon R; Quan QZ; Oh DH; Kim JO; Hwang MR; Koo YB; Woo JS; Yong CS; Choi HG
    Arch Pharm Res; 2009 May; 32(5):767-72. PubMed ID: 19471892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
    Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
    J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier.
    Ghanavati R; Taheri A; Homayouni A
    Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():501-511. PubMed ID: 28024614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.
    Shuai S; Yue S; Huang Q; Wang W; Yang J; Lan K; Ye L
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):413-22. PubMed ID: 25669445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the use of spray congealing to produce solid dispersions with enhanced indomethacin bioavailability: In vitro characterization and in vivo study.
    Bertoni S; Albertini B; Ferraro L; Beggiato S; Dalpiaz A; Passerini N
    Eur J Pharm Biopharm; 2019 Jun; 139():132-141. PubMed ID: 30910731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.
    McNamara DP; Childs SL; Giordano J; Iarriccio A; Cassidy J; Shet MS; Mannion R; O'Donnell E; Park A
    Pharm Res; 2006 Aug; 23(8):1888-97. PubMed ID: 16832611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil.
    Wlodarski K; Sawicki W; Haber K; Knapik J; Wojnarowska Z; Paluch M; Lepek P; Hawelek L; Tajber L
    Eur J Pharm Biopharm; 2015 Aug; 94():106-15. PubMed ID: 25998701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel High-Drug-Loaded Amorphous Dispersion Tablets of Posaconazole;
    Mudie DM; Stewart AM; Biswas N; Brodeur TJ; Shepard KB; Smith A; Morgen MM; Baumann JM; Vodak DT
    Mol Pharm; 2020 Dec; 17(12):4463-4472. PubMed ID: 32835489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium Lauryl Sulfate Competitively Interacts with HPMC-AS and Consequently Reduces Oral Bioavailability of Posaconazole/HPMC-AS Amorphous Solid Dispersion.
    Chen Y; Wang S; Wang S; Liu C; Su C; Hageman M; Hussain M; Haskell R; Stefanski K; Qian F
    Mol Pharm; 2016 Aug; 13(8):2787-95. PubMed ID: 27337060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor.
    Cui Y; Chiang PC; Choo EF; Boggs J; Rudolph J; Grina J; Wenglowsky S; Ran Y
    Int J Pharm; 2013 Sep; 454(1):241-8. PubMed ID: 23834830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: pros and cons.
    Chokshi RJ; Zia H; Sandhu HK; Shah NH; Malick WA
    Drug Deliv; 2007 Jan; 14(1):33-45. PubMed ID: 17107929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an Amorphous Solid Dispersion Formulation for Mitigating Mechanical Instability of Crystalline Form and Improving Bioavailability for Early Phase Clinical Studies.
    Chiang CW; Lubach JW; Chen T; Chin S; Ly J; Zhang W; Hou HH; Nagapudi K
    Mol Pharm; 2023 May; 20(5):2452-2464. PubMed ID: 37010134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.